Russell Frank Company’s Teva Pharmaceuticals TEVA Stock Holding History

Russell Frank Company’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$161M	Sell	3,012,076 -436,032	-13%	-$25.6M	0.28%	64
2015 Q4	$228M	Sell	3,448,108 -335,419	-9%	-$20.7M	0.4%	42
2015 Q3	$214M	Sell	3,783,527 -399,406	-10%	-$25.9M	0.4%	41
2015 Q2	$247M	Buy	4,182,933 +251,860	+6%	+$15.5M	0.4%	38
2015 Q1	$245M	Sell	3,931,073 -652,211	-14%	-$37.9M	0.45%	29
2014 Q4	$261M	Sell	4,583,284 -103,958	-2%	-$5.79M	0.46%	26
2014 Q3	$252M	Buy	4,687,242 +641,124	+16%	+$34M	0.45%	30
2014 Q2	$216M	Sell	4,046,118 -685,661	-14%	-$35M	0.38%	47
2014 Q1	$234M	Buy	4,731,779 +366,469	+8%	+$16.9M	0.41%	39
2013 Q4	$195M	Buy	4,365,310 +888,005	+26%	+$35M	0.36%	50
2013 Q3	$131M	Sell	3,477,305 -212,299	-6%	-$8.28M	0.23%	91
2013 Q2	$145M	Buy	+3,689,604	New	+$144M	0.26%	78

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Russell Frank Company's TEVA Position: Q1 2016 in Review

Russell Frank Company reduced its Teva Pharmaceuticals (TEVA) stake by 13% in Q1 2016, selling an estimated $25.6M and leaving 3,012,076 shares worth $161M. The position accounts for 0.28% of the portfolio, ranked #64.

Russell Frank Company first reported a position in TEVA in Q2 2013 and has held it in 12 quarters since. The position peaked at $261M in Q4 2014. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Russell Frank Company held 3,012,076 shares of Teva Pharmaceuticals worth $161M as of Q1 2016.
Russell Frank Company sold 436,032 Teva Pharmaceuticals shares in Q1 2016, an estimated $25.6M.
Teva Pharmaceuticals made up 0.28% of Russell Frank Company's portfolio in Q1 2016, its #64 holding.
Russell Frank Company first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 12 quarters since.
Russell Frank Company's Teva Pharmaceuticals position peaked at $261M in Q4 2014.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.